Yıl: 2022 Cilt: 10 Sayı: 3 Sayfa Aralığı: 265 - 269 Metin Dili: Türkçe DOI: 10.4274/nkmj.galenos.2022.31932 İndeks Tarihi: 17-10-2022

Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü

Öz:
Amaç: Çalışmamızın amacı aşikar diyabeti olmayan hastalarda insülin direncinin (IR) atriyal fibrilasyon (AF) ile ilişkisini araştırmaktır. Gereç ve Yöntem: Çalışmamıza 18 yaş ve üzeri hipertansiyon dışında kronik hastalığı olmayan hastalar dahil edildi. Hastaların tıbbi öyküleri alındı, fizik muayeneleri ve kan tahlilleri yapıldı ve elektrokardiyografileri çekildi. Tetkiklerinde aşikar diyabet saptanan hastalar çalışma dışı bırakıldı. Hastalar normal sinüs ritminde (NSR) olan grup ve AF’si olan grup olmak üzere ikiye ayrıldı ve IR analiz edildi. Bulgular: Çalışmaya 132’si (%66) NSR’de ve 68’i (%34) AF ritminde olan toplam 200 hasta (108 kadın, yaş ortalaması 67,33±8,37 yıl) dahil edildi. NSR’de ve AF ritminde olan hastalar arasında açlık plazma glikoz seviyeleri açısından fark bulunmazken (sırası ile 102,65±7,49 mg/dL ve 99,68±9,46 mg/dL; p=0,09), açlık insülin düzeyi açısından anlamlı bir fark tespit edildi (sırasıyla 11,06±2,71 mg/dL ve 8,48±2,64 mg/dL; p<0,0001). İnsülin direnci [homeostatik model değerlendirmesi (homeostatic model assessment HOMA-IR)] ortalaması AF grubunda NSR grubuna göre anlamlı düzeyde yüksek tespit edildi (sırası ile 2,90±0,79 ve 2,10±0,46; p<0,0001). İnsülin direnci olan (HOMA-IR >2,4) hastaların oranı AF grubunda NSR grubuna göre anlamlı olarak daha yüksek bulundu (sırasıyla %76,47 ve %28,78; p<0,0001). Regresyon analizleri yapıldı. Çok değişkenli regresyon analizi HOMA IR’deki her bir birimlik artışın AF riskini 2,56 kat artırdığını gösterdi. Sonuç: Diyabet ve AF birlikteliğinin sık görülmesinde ana faktörün hiperglisemiden çok, öncesinde gelişen IR olduğu düşünülmüştür. IR’nin erken tespiti ve tedavisi, AF gelişimini ve ilişkili morbidite ve mortaliteyi azaltabilir.
Anahtar Kelime:

Role of Insulin Resistance in the Development of Atrial Fibrillation

Öz:
Aim: To investigate the relationship between insulin resistance (IR) and atrial fibrillation (AF) in patients without overt diabetes. Materials and Methods: Patients aged ≥18 years without chronic disease other than hypertension were included in the study. Medical histories were obtained, and detailed physical examination, blood tests and electrocardiography were performed. Patients with overt diabetes were excluded from the study. The patients were evaluated in two groups [normal sinus rhythm (NSR) and AF groups]. The presence of IR was analyzed. Results: Two hundred patients (the mean age, 67.33±8.37 years; 108 females), of whom 132 (66%) had NSR and 68 (34%) had AF, were included in the study. There was no difference between the groups regarding fasting plasma glucose levels (102.65±7.49 mg/dL and 99.68±9.46 mg/dL, respectively; p=0.09). A significant difference was found regarding fasting insulin levels (11.06±2.71 mg/dL and 8.48±2.64 mg/dL, respectively; p<0.0001). The mean IR [homeostatic model assessment (HOMA-IR)] was significantly higher in the AF group than in the NSR group (2.90±0.79 and 2.10±0.46, respectively; p<0.0001). The proportion of patients with IR (HOMA-IR >2.4) was significantly higher in the AF group than in the NSR group (76.47% and 28.78%, respectively; p<0.0001). Regression analyses were performed. Multivariate regression analysis showed that each unit increase in HOMA-IR increased the risk of AF for 2.56-fold. Conclusion: The main factor for the frequent coexistence of diabetes mellitus and AF was considered to be IR rather than hyperglycemia. Early detection and treatment of IR can reduce AF development and associated morbidity and mortality.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;40:e125-51.
  • Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108:56-62.
  • Polovina M, Krljanac G, Ašanin M, Seferović PM. Crouching tiger, hidden dragon: insulin resistance and the risk of atrial fibrillation. Eur J Prev Cardiol. 2020;27:1931-3.
  • Lee Y, Cha SJ, Park JH, Shin JH, Lim YH, Park HC, et al. Association between insulin resistance and risk of atrial fibrillation in non-diabetics. Eur J Prev Cardiol. 2020;27:1934-41.
  • Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-322.
  • Cho ME, Craven TE, Cheung AK, Glasser SP, Rahman M, Soliman EZ, et al. The association between insulin resistance and atrial fibrillation: A crosssectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial). J Clin Hypertens (Greenwich). 2017;19:1152-61.
  • Fontes JD, Lyass A, Massaro JM, Rienstra M, Dallmeier D, Schnabel RB, et al. Insulin resistance and atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109:87-90.
  • Kallistratos MS, Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertension. Pharmacol Res. 2018;128:322-6.
  • Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial Fibrillation and Hypertension. Hypertension. 2017;70:854-61.
  • Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014;114:1217-22.
  • Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019;21:210-7.
  • Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, et al. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18:125.
  • Zhang Z, Zhang X, Korantzopoulos P, Letsas KP, Tse G, Gong M, et al. Thiazolidinedione use and atrial fibrillation in diabetic patients: a metaanalysis. BMC Cardiovasc Disord. 2017;17:96.
  • Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123.
  • O’Brien TP, Jenkins EC, Estes SK, Castaneda AV, Ueta K, Farmer TD, et al. Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle. Diabetes. 2017;66:1172-84.
  • Mou L, Norby FL, Chen LY, O’Neal WT, Lewis TT, Loehr LR, et al. Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol. 2018;11:e006350.
  • Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154-62.
  • Wolbrette D, Naccarelli G, Curtis A, Lehmann M, Kadish A. Gender differences in arrhythmias. Clin Cardiol. 2002;25:49-56.
  • Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:1501-8.
  • Wang TJ, Parise H, Levy D, D’Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471-7.
  • Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med. 2005;118:489-95.
  • Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J. 2008;155:310-5.
  • Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-60.
APA Yigit E, Erciyes D (2022). Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. , 265 - 269. 10.4274/nkmj.galenos.2022.31932
Chicago Yigit Ece,Erciyes Demet Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. (2022): 265 - 269. 10.4274/nkmj.galenos.2022.31932
MLA Yigit Ece,Erciyes Demet Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. , 2022, ss.265 - 269. 10.4274/nkmj.galenos.2022.31932
AMA Yigit E,Erciyes D Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. . 2022; 265 - 269. 10.4274/nkmj.galenos.2022.31932
Vancouver Yigit E,Erciyes D Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. . 2022; 265 - 269. 10.4274/nkmj.galenos.2022.31932
IEEE Yigit E,Erciyes D "Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü." , ss.265 - 269, 2022. 10.4274/nkmj.galenos.2022.31932
ISNAD Yigit, Ece - Erciyes, Demet. "Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü". (2022), 265-269. https://doi.org/10.4274/nkmj.galenos.2022.31932
APA Yigit E, Erciyes D (2022). Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. Namık Kemal Tıp Dergisi, 10(3), 265 - 269. 10.4274/nkmj.galenos.2022.31932
Chicago Yigit Ece,Erciyes Demet Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. Namık Kemal Tıp Dergisi 10, no.3 (2022): 265 - 269. 10.4274/nkmj.galenos.2022.31932
MLA Yigit Ece,Erciyes Demet Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. Namık Kemal Tıp Dergisi, vol.10, no.3, 2022, ss.265 - 269. 10.4274/nkmj.galenos.2022.31932
AMA Yigit E,Erciyes D Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. Namık Kemal Tıp Dergisi. 2022; 10(3): 265 - 269. 10.4274/nkmj.galenos.2022.31932
Vancouver Yigit E,Erciyes D Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü. Namık Kemal Tıp Dergisi. 2022; 10(3): 265 - 269. 10.4274/nkmj.galenos.2022.31932
IEEE Yigit E,Erciyes D "Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü." Namık Kemal Tıp Dergisi, 10, ss.265 - 269, 2022. 10.4274/nkmj.galenos.2022.31932
ISNAD Yigit, Ece - Erciyes, Demet. "Atriyal Fibrilasyon Gelişiminde İnsülin Direncinin Rolü". Namık Kemal Tıp Dergisi 10/3 (2022), 265-269. https://doi.org/10.4274/nkmj.galenos.2022.31932